Securities Code: 300639
Securities Abbreviation: Kaipu Bio
Announcement No.: 2026-044
Guangdong Kaipu Biological Technology Co., Ltd.
Announcement on Accumulated Litigation and Arbitration Matters
The Company and the entire Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Guangdong Kaipu Biological Technology Co., Ltd. (hereinafter referred to as the "Company") has, in accordance with the "Rules Governing the Listing of Stocks on the ChiNext Market of the Shenzhen Stock Exchange" and other relevant regulations, compiled statistics on the accumulated litigation and arbitration matters of the Company and its subsidiaries within the consolidated financial statements over the past twelve months. The total amount involved has reached the information disclosure standard. The relevant situation is hereby announced as follows:
I. Basic Situation of Accumulated Litigation and Arbitration Matters
According to the "Rules Governing the Listing of Stocks on the ChiNext Market of the Shenzhen Stock Exchange" and other relevant regulations, as of the date of this announcement, the Company and its subsidiaries within the consolidated financial statements have accumulated a total of 59 litigation and arbitration matters within twelve months. These primarily involve the period from 2020 to 2022. The cases mainly relate to customers who have defaulted on payments for goods or testing services provided by the Company, or outstanding service fees owed by customers in related cooperation agreements. The total amount involved is RMB 41,000.10 million, accounting for 10.94% of the company's net assets attributable to shareholders as of the most recent audited period.